|

Buserelin Clinical Trials

1 actively recruiting trial across 1 location

Also known as: 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766 +9 more

Pipeline

Phase 3: 1

Top Sponsors

  • NRG Oncology1

Indications

  • Prostate Adenocarcinoma1
  • Cancer1

Birmingham, Alabama1 trial

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

University of Alabama at Birmingham Cancer Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.